Mirum Pharmaceuticals (MIRM) Cost of Revenue (2023 - 2025)
Historic Cost of Revenue for Mirum Pharmaceuticals (MIRM) over the last 3 years, with Q3 2025 value amounting to $25.5 million.
- Mirum Pharmaceuticals' Cost of Revenue rose 2273.86% to $25.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.8 million, marking a year-over-year increase of 1296.21%. This contributed to the annual value of $81.6 million for FY2024, which is 7356.45% up from last year.
- Mirum Pharmaceuticals' Cost of Revenue amounted to $25.5 million in Q3 2025, which was up 2273.86% from $23.4 million recorded in Q2 2025.
- Mirum Pharmaceuticals' Cost of Revenue's 5-year high stood at $25.5 million during Q3 2025, with a 5-year trough of $5.0 million in Q1 2023.
- Over the past 3 years, Mirum Pharmaceuticals' median Cost of Revenue value was $20.8 million (recorded in 2024), while the average stood at $18.2 million.
- Data for Mirum Pharmaceuticals' Cost of Revenue shows a peak YoY increase of 25810.4% (in 2024) and a maximum YoY decrease of 895.28% (in 2024) over the last 5 years.
- Quarter analysis of 3 years shows Mirum Pharmaceuticals' Cost of Revenue stood at $25.0 million in 2023, then fell by 8.95% to $22.8 million in 2024, then grew by 12.1% to $25.5 million in 2025.
- Its last three reported values are $25.5 million in Q3 2025, $23.4 million for Q2 2025, and $23.0 million during Q1 2025.